Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issue
17-3
Table of Contents
Editors Selection
Glaucoma Dialogue
Glaucoma Opinion
Abstracts
Abstracts
Abstracted Journals
Classification List
Index of Authors
Search
Home
Abstracts
Journals
Journal #483
advertisement
Eye
21
Showing records 1 to 21 |
Display all abstracts in
Eye
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Srinivasan S
Eye
2016; 30: 362-368
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Quartilho A
Eye
2016; 30: 602-607
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Groen F
Eye
2016; 30: 473-480
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Olmos LC
Eye
2016; 30: 463-472
65881
A view on glaucoma-are we seeing it clearly?
Crabb DP
Eye
2016; 30: 304-313
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Simkiss P
Eye
2016; 30: 602-607
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Choudhari NS
Eye
2016; 30: 362-368
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Sayed MS
Eye
2016; 30: 463-472
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Ramdas W; de Hoog J
Eye
2016; 30: 473-480
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Baskaran M
Eye
2016; 30: 362-368
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Moraczewski AL
Eye
2016; 30: 463-472
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Zekite A
Eye
2016; 30: 602-607
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
George RJ
Eye
2016; 30: 362-368
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Vingerling JR
Eye
2016; 30: 473-480
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Xing W
Eye
2016; 30: 602-607
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Gedde SJ; Rosenfeld PJ
Eye
2016; 30: 463-472
66602
Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Rothova A
Eye
2016; 30: 473-480
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Shantha B
Eye
2016; 30: 362-368
66513
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Wormald R; Bunce C
Eye
2016; 30: 602-607
65930
Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Vijaya L
Eye
2016; 30: 362-368
66340
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Shi W; Feuer WJ; Lee RK
Eye
2016; 30: 463-472
Issue
17-3
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
24-1 (2024)
23-4 (2023)
23-3 (2023)
23-2 (2023)
23-1 (2022)
22-4 (2022)
22-3 (2022)
22-2 (2021)
22-1 (2021)
21-4 (2021)
21-3 (2021)
21-2 (2021)
21-1 (2020)
20-4 (2020)
20-3 (2020)
20-2 (2019)
20-1 (2019)
19-4 (2019)
19-3 (2018)
19-2 (2018)
19-1 (2018)
18-4 (2017)
18-3 (2017)
18-2 (2017)
18-1 (2017)
17-4 (2016)
17-3 (2016)
17-2 (2016)
17-1 (2016)
16-4 (2015)
16-3 (2015)
16-2 (2015)
16-1 (2014)
15-4 (2014)
15-3 (2014)
15-2 (2013)
15-1 (2013)
14-4 (2013)
14-3 (2013)
14-2 (2013)
14-1 (2012)
13-4 (2012)
13-3 (2011)
13-2 (2011)
13-1 (2011)
12-4 (2011)
12-3 (2010)
12-2 (2010)
12-1 (2010)
11-4 (2010)
11-3 (2009)
11-2 (2009)
11-1 (2009)
10-4 (2009)
10-3 (2008)
10-2 (2008)
10-1 (2008)
9-4 (2008)
9-3 (2007)
9-2 (2007)
9-1 (2007)
8-4 (2007)
8-3 (2006)
8-2 (2006)
8-1 (2006)
7-3 (2006)
7-2 (2005)
7-1 (2005)
6-3 (2005)
6-2 (2004)
6-1 (2004)
5-3 (2004)
5-2 (2003)
5-1 (2003)
4-3 (2003)
4-2 (2002)
4-1 (2002)
3-3 (2002)
3-2 (2001)
3-1 (2001)
2-3 (2001)
2-2 (2000)
2-1 (2000)
1-3 (2000)
1-2 (1999)
1-1 (1999)
advertisement